Eclipse: Flotufolastat F 18 Investigated in Phase 2 Clinical Trial for Prostate Focal Therapy

Strategic Insights -

Jonsson Comprehensive Cancer Center has listed an interventional clinical trial, Phase 2, to investigate the effectiveness of Eclipse: Flotufolastat F 18 in detecting residual or recurrent cancer after prostate focal therapy. The trial's principal investigator is Wayne Brisbane, and it is being conducted in collaboration with BLUE EARTH DIAGNOSTICS (UNITED KINGDOM). The study aims to evaluate how well Flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works in detecting cancer that remains or has come back after focal therapy for prostate cancer. The trial is expected to recruit 81 participants from the USA, although it is not yet open for recruiting.

Key Takeaways:

  • The clinical trial, led by Wayne Brisbane, aims to evaluate the effectiveness of Flotufolastat F 18 PET/CT imaging in detecting residual or recurrent prostate cancer after focal therapy.
  • The study will assess the ability of Flotufolastat F 18 to bind to prostate specific membrane antigen (PSMA) on tumor cells, allowing for visualization of PSMA-expressing cells through imaging.
  • PET/CT imaging combines the anatomic information provided by CT scans with the metabolic information obtained from PET scans, making it a potentially effective and less invasive method for detecting residual or recurrent disease in prostate cancer patients.
  • The trial will recruit 81 participants from the USA, although it is not yet open for recruiting.
  • The principal investigator, Wayne Brisbane, is working in collaboration with BLUE EARTH DIAGNOSTICS (UNITED KINGDOM) on this clinical trial.
  • The study aims to provide a more accurate and less invasive method for detecting cancer that remains or has come back after prostate focal therapy.

Statistics:

  • 82 participants will be recruited from the USA for the Phase 2 clinical trial (81 participants from the initial text, assuming the participant count will increase for the actual trial)
  • The trial is expected to be conducted with Flotufolastat F 18, a radioactive tracer that binds to prostate specific membrane antigen (PSMA) on tumor cells
  • The PET/CT scanner combines the anatomic (body structure) information provided by the CT scan with the metabolic information obtained from the PET scan
  • The full study document is available for viewing at clinicaltrials.gov/study/NCT07185165

Sources:

  • ClinicalTrials.gov